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Abstract
The level of circulating vitamin D is known to be associated with the ejection
fraction in heart failure patients and studies in rats have shown that vitamin
D depletion leads to increased levels of circulating norepinephrine and
decreased atrial contractility. We elucidated the effects of vitamin D supple-
mentation on the autonomous nervous system in healthy youngsters. Thirty
healthy subjects aged 18–25 years were recruited based on their serum 25-
hydroxyvitamin D (25[OH]D): 15 vitamin D insufficient (25[OH]
D < 50 nmol/L) and 15 vitamin D sufficient (25[OH]D > 80 nmol/L) sub-
jects. Both groups had vitamin D supplementation (30 microg/day) and were
tested at baseline and after 30, 90, and 180 days. At each visit the serum 25-
hydroxyvitamin D was measured and the head-up tilt test performed. Serum
25[OH]D remained stable in the vitamin D sufficient group, while the insuffi-
cient group had a significant increase (32.0–64.5 nmol/L), P < 0.0001. Despite
the increase, the insufficient group did not reach the level of the vitamin D
sufficient group within the 6 months observational period (96.1 vs 64.5 nmol/
L), P < 0.01. Serum norepinephrine at baseline was higher in the insufficient
group (mean = 1.61 nmol/L) than in the vitamin D sufficient group
(mean = 0.94 nmol/L), P < 0.01, whereas the response to tilt was lower in the
insufficient group (mean = 0.69 nmol/L) compared to the sufficient group
(mean = 1.17 nmol/L), P < 0.01. The heart rate at rest was higher in the
insufficient group (mean = 67.7 bpm) than in the vitamin D sufficient group
(mean = 56.6 bpm), P < 0.01, for the three first visits. At the last visit no dif-
ference was found. The systolic and diastolic blood pressure differed between
the groups after a month, with higher pressures in the insufficient group than
in the sufficient group. Vitamin D supplementation modulates the sympa-
thetic nervous system in healthy youngsters with low serum vitamin D. The
observation might lead to a greater focus on possible prevention of cardiac
disease later on in life by vitamin D supplementation early in life.
Introduction
Heart failure is associated with low 25-hydroxyvitamin D
(25-[OH]D) levels (Lee et al. 2008) and altered nore-
pinephrine (NorEp) levels (Thomas and Marks 1978;
Cohn et al. 1984). Vitamin D supplementation has
recently been shown to improve ejection fraction in heart
failure patients (Dalbeni et al. 2014) and has been
associated with improvement of cardiac tone (Mann et al.
2014).
Previous studies in animals have provided valuable
insight regarding the possible mechanisms behind the
association. First, in Sprague-Dawley rats (SDRs), a vita-
min D-depleted diet leads to increased circulating NorEp
(Baksi and Hughes 1984), and decreased atrial contractil-
ity when stimulated with NorEp, suggesting a decreased
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atrial sensibility to NorEp caused by the vitamin D deple-
tion (Baksi and Hughes 1986). Second, a vitamin D-free
diet induced an increase in the systolic blood pressure
and the mean arterial pressure in SDRs (Baksi 1988),
which could be explained by the increase circulating levels
of NorEp (Baksi and Hughes 1984). Shermann rats (S)
fed a vitamin D-free diet for 30 days resulted in adrenal
glands with high concentration of NorEp, low pheny-
lethanolamine-N-methyltransferase activity, and normal
epinephrine levels.
In vivo administration of 1a,25-dihydroxycholecalciferol
(1a,25[OH]2D3) has also been found to have a cardiovas-
cular effect. Doses of 1a,25[OH]2D3 in vivo lead to
increased contractility of resistance arteries (measured in
mesenteric artery) when stimulated with NorEp, which
was found in single, short, and long-term administration
studies (Bukoski et al. 1990, 1993; Bukoski and Xue 1993;
Hatton et al. 1994) in SHRs and in single and short-term
studies in Wister-Kyoto rats (WKR) (Bukoski et al. 1990;
Bukoski and Xue 1993). This positive inotropic effect is
also found in Wistar rats (WR) and is most likely the
result of increased Ca2+-channel-mediated Ca2+influx
(Bian et al. 1996). Administration of 1,25[OH]2D3 in vivo
favors bolus administration over continuous administra-
tion with regard to the positive inotropic effect of 1,25
[OH]2D3 (Hatton et al. 1994). In rats, the modulation of
vitamin D content in the diet affects circulating NorEp
concentrations, the systolic blood pressure, and the con-
tractility of the atria. Administration of 1,25[OH]2D3
in vivo modulates the contractility of the atria and
increases the contractility of the resistance arteries but
does not affect the blood pressure. The link between 1,25
[OH]2D3 and cardiovascular function is reproduced in
healthy dogs (Jahn et al. 1991; Jespersen et al. 1998).
Based on this overlap in clinical findings and results from
animal studies, we hypothesized a relationship between
vitamin D status, circulating NorEp and cardiovascular
function. The aim of this study was to investigate the effect
of increasing 25[OH]D by vitamin D + calcium supple-
mentation on the sympathetic nervous system. We con-
ducted head-up tilt table (HUT) testing repeatedly during
vitamin D supplementation and explored the associations
between 25[OH]D, circulating NorEp, heart rate, and
blood pressure before and after HUT in normal healthy
young adults just differing in the level of circulating vita-
min-D.
Subjects and Methods
The study was carried out from October 2012 to August
2014 as a single center, parallel cohort, clinical controlled
trial conducted at the Department of Clinical Physiology,
Nuclear Medicine & PET, Rigshospitalet Glostrup.
The Inclusion criteria were 18–25 years of age and
either sex. The exclusion criteria included: pregnancy, a
disease known to interfere with vitamin D, hypertension,
heart or kidney disease, diabetes, epilepsy, bone disease,
use of systemic anabolic steroids, or supplementation or
drug treatment known to affect parameters of measure-
ment. Each subject’s respective vitamin D level is a result
of their lifestyle and genes as all participants were na€ıve
to vitamin D supplementation in any form or combina-
tion.
We recruited from a larger cohort (n = 99) of healthy
young adults aged 18–25 years who participated in a
study of S-25[OH]D and bone mineral density (Tonnesen
et al. 2016). On the basis of their S-25[OH]D values, we
recruited individuals for two groups, each with 15 partici-
pants with either vitamin D insufficiency (S-25[OH]
D < 50 nmol/L) or vitamin D sufficieny (S-25[OH]
D > 80 nmol/L.
We invited 60 subjects, of whom 27 had sufficient
vitamin D and 33 had insufficient vitamin D levels, by e-
mail. We halted recruitment when 15 vitamin D suffi-
cient and 15 vitamin D insufficient subjects had accepted
the invitation. The 25[OH]D level in serum was remea-
sured on the first day of the study to assure that 25[OH]
D had not changed significantly since initial screening.
Figure 1.
Written informed consent was obtained prior to partic-
ipation. The local ethical committee (Ethical Committee
for the Capital Region, Denmark (Region Hovedstaden))
approved this study, with ref. No. H-1-2012-023.
Study program
The program comprised four visits for evaluation of the
sympathetic nervous system with a head-up tilt test before
supplementation with vitamin D, and 30 days, 90 days,
and 180 days after initiation of vitamin D supplementa-
tion. All visits took place between 08.00 and 17.00; partic-
ipants had fasted for 2 h prior to all visits. Height and
weight were measured at start.
Intervention
Both groups were given vitamin D3 + calcium supple-
mentation. The vitamin-D-insufficient group was supple-
mented to increase the concentration of S-25[OH]D. The
vitamin D sufficient group, that acted as the control
group, aimed at a steady S-25[OH]D concentration above
the calculated lower boundary.
All participants were supplied with 180 tablets of vita-
min D3 10 lg/tablet and calcium 400 mg calcium in a
personal container during the study period and were
instructed to take three tablets a day for a daily dose of
2018 | Vol. 6 | Iss. 7 | e13635
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30 lg vitamin D3 + 1200 mg calcium. The participants
were instructed to bring all supplied containers and
remaining tablets to their next visit for compliance esti-
mation.
Protocol
Evaluation of the sympathetic nervous system was con-
ducted in a quiet room with dimmed lights and a com-
fortable temperature. A tilt table with a footboard
support was used. We used two body positions: supine
and 60 degree head up tilt test. Participants were first
given peripheral i.v. access for blood sampling in the
supine position and attached to the tilt table with straps.
Participants rested 30 min for baseline values of blood
pressure, heart rate and blood samples for the assessment
of S-25[OH]D and the two catecholamines; nore-
pinephrine (NorEp) and epinephrine (Ep), hereafter the
term catecholamines refers to NorEp and Ep combined.
After assessment of the baseline values, participants were
tilted to 60-degrees head up for the next 30 min. Cate-
cholamines were sampled again after 15 min unless the
subject fainted before that; if fainting occurred, the cate-
cholamine levels were sampled at the time of the faint.
After 30 min with the head up, the subject was placed in
the supine position for recovery.
Measurements
Sympathetic nervous system activity
The activity of the sympathetic nervous system (SNS) was
assessed from the spillover of Ep and NorEp into the cir-
culation. Blood samples were obtained in prechilled
EDTA-tubes and centrifuged at 1500 g at 5°C for 10 min;
the samples were subsequently stored at 80 until analy-
sis. serum NorEp and Ep were analyzed with a radio
immuno assay (RIA) (2-Cat RIA, Labor Diagnostika
Nord, Nordhon Germany). The Ep range was 0.0082–
8.2 nmol/L with a sensitivity of 0.0027 nmol/L and inter-
assay coefficient of variance (CV) 3.5% and intra-assay
CV 4.0%. For NorEp, the range was 0.36–35.5 nmol/L,
sensitivity was 0.15 nmol/L with inter-assay CV 2.5% and
intra-assay CV 3.2%.
Responders (n = 60)
1. Visit. (n = 14)
Missing data: Epinephrine at rest (n = 1), 
2. Visit (n = 13), withdrew (n = 1)
Missing data: epinephrine at rest (n = 1)
3. Visit. (n = 12), withdrew (n = 1)
Missing data: none
4. Visit. (n = 11), withdrew (n = 1)
Missing data: Norepinephrine at rest 
(n = 1), Norepinephrine at tiltup (n = 2) 
1. Visit. (n = 13)
Missing data: None
2. Visit (n = 12), withdrew (n = 1)
Missing data: None
3. Visit. (n = 12), withdrew (n = 0)
Missing data: None
4. Visit. (n = 10), withdrew (n = 2)
Missing data: Epinephrine at tiltup (n = 1)
Excluded
Reassessed S-25[OH]D differs from 
inclusion criteria (n = 3)
Vitamin D sufficient 
S-25[OH]D > 80 nmol/L
Vitamin D insufficient
S-25[OH]D < 50 nmol/L
Invitation accepted (n = 30)
Not assessed
No response to invitation (n = 30)
Cohort based on screening from previous study (n = 99)
Figure 1. Flow diagram of recruiting and progress through the phases of a parallel-group, investigative cohort study.
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Serum-25-Hydroxyvitamin D
The measurement of 25[OH]D in the serum was based on
blood samples obtained in tubes with serum clot activator
that were subsequently centrifuged at 1500 g at 10 min.
The serum was frozen at 20°C until analysis with the
chemiluminescent immunoassay (Liaison 25-OH Vitamin
D Total Assay; Diasorin Inc., Saluggia (Vercelli), Italy). 25-
hydroxyvitamin D was analyzed in the routine laboratory,
inter-assay CV 9.1–9.8% and intra-assay 2.5%.
Hemodynamic monitoring
Noninvasively cardiovascular assessment with continous
heart-rate and beat-to-beat blood pressure (TaskForce:
CNSystems, Graz, Austria). The coefficient of variation for
the sBP and dBP was 6.8% for both. The cardiac output
measured by impedance cardiography was not measured,
even though the TaskForce-system allowed it. Electrocar-
diogram electrodes were placed in six limb leads configura-
tion to measure heart rate (HR). Systolic and diastolic
blood pressures were measured both with beat-to-beat
applying finger-plethysmography and with an arm cuff.
Statistics
Sample size for the primary outcome of catecholamines
was based on the least relevant effect size of 0.5 nmol/L
with an SD = 0.4 nmol/L, a = 0.05, and b = 0.80; we cal-
culated a sample size of 12 subjects for each group. For
continuous data, visual inspection was applied to deter-
minate distribution. Unadjusted continuous data are
reported as the mean  SD when data follow a normal
distribution and as median and interquartile range (IQR)
when they did not. Categorical variables are summarized.
Baseline values were tested using the unpaired Student’s
t-test or v2-test.
Boundaries to detect if subjects had crossed-over from
one group to another in the time from screening to entry
was calculated as limit  2  CV  limit, a CV of 9.8% was
used. The upper limit for vitamin-D-insufficient group was
50 nmol/L and the boundary calculated to 60 nmol/L. The
lower limit for the vitamin-D-sufficient group was
80 nmol/L and boundary was calculated 64 nmol/L.
A mixed model was applied to take advantage of
repeated measurements and mixed random and fixed
effects and address missing data. Missing data were
assumed missing at random. The fixed effects were sex
and vitamin D level. Estimates are adjusted for sex and
reported estimated means with 95% Cl. The level of the
individuals physical activity was not significant and was
excluded from the final model.
Comparison of simple effects was performed at each
visit without separating data in one analysis to test for
the effect of vitamin D + calcium supplementation. For
all statistics (SAS Version 9.3, Cary, NC) was used. We
considered a P-value of 0.05 to be statistically significant.
Results
Based on the screening values of S-25[OH]D, we invited
by e-mail 27 and 33 subjects with sufficient and insuffi-
cient serum vitamin D, respectively. Fifteen subjects from
each invited group accepted the invitation. Time from
screening to study entry was not different between
groups. After reassessment of S-25[OH]D we excluded
two participant with insufficiency and one with defi-
ciency, as their S-25[OH]D concentrations had changed
significantly since screening. Not all participants com-
pleted all four visits; three in the sufficient group and
three in the insufficient group dropped out. Flowchart for
recruiting and progress of study is given in Figure 1.
The analysis comprised 11 men with a mean age of
20.4  1.7 and 16 women with a mean age of
21.0  2.2. The characteristics of the participants at base-
line visit are listed in Table 1. At the baseline visit, the
vitamin D insufficient group had lower S-25[OH]D levels,
lower physical activity, higher HR, higher NorEp levels
compared with the sufficient group.
The period of vitamin D + calcium supplementation
(median [IQR]) was 184 [180–200] days for the insuffi-
cient group and 183 [179–200] days for the control
group. Compliance (mean) for the insufficient and suffi-
cient group, respectively was from visit one to two; 83%
and 81%, from visit two to three; 84% and 82%, and
from visit three to four 90% and 87%.
From the baseline visit to the fourth visit, the vitamin
D insufficient group increased their S-25[OH]D by 32.3
(21.6–42.9)nmol/L, P < .0001, and the vitamin D levels in
the sufficient group remained steady with a change in S-
25[OH]D of 5.9 (16.1 to 4.3) nmol/L, P = 0.25. The
vitamin D sufficient group remained higher in S-25[OH]
D levels at all visits compared to the insufficient group,
P = 0.0001, see Figure 2A.
Epinephrine and Norepinephrine
NorEp at rest was significantly higher in the insufficient
group at the first and second visits compared to the suffi-
cient group, with an estimated difference of 0.65 (0.35–
0.96) nmol/L, P < .0001 and 0.50 (0.08–0.91) nmol/L,
P = 0.02, respectively. At the third visit, the difference
was insignificant and had further diminished at the fourth
visit; see Figure 2A for the unadjusted values and Fig-
2018 | Vol. 6 | Iss. 7 | e13635
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ure 2B for the plot of adjusted values. Stimulation with
HUT led to an increase in NorEp; at the first visit, the
increase was significantly higher in the sufficient group
1.17 (0.95–1.38) nmol/L compared with the insufficient
group 0.69 (0.48–0.91) nmol/L, P = 0.003. At visits two
through four, there was no significant difference in the
NorEp increase between the groups; for the HUT-induced
increase in NorEp, see Figure 2C. The effect of vitamin
D + calcium supplementation on the NorEp changes
induced by HUT is present from visits two through four;
see Table 2 for values and Figure 2D for the trend line.
NorEp is the major driver of change in the levels of
catecholamines rather than Ep, and this change accounts
for both values at rest and in response to HUT stimula-
tion. No significant changes in epinephrine between and
within groups were found neither at rest nor after HUT
stimulation.
Heart rate
At rest, the mean heart rate was significantly higher from
the first to the third visit in the sufficient group com-
pared to the insufficient group, and at visit four, the
between group difference had disappeared. Stimulation
with HUT led to an increase in HR in both groups as
expected. In the insufficient group, HUT at the first
visit led to an increase in 14.7 (8.2–21.2) bpm. From
visit one to two, it increased 9.2 (1.4–17.1) bpm;
P = 0.02–23.9 (17.2–30.6) bpm. At the second visit, the
difference in bpm remained the same as for the subse-
quent visits. For the sufficient group, the increase in
HR when stimulated with HUT remained stable from
the first through the last visits; see Table 2 and Fig-
ure 2E. The treatment effect on heart rate response to
HUT was present at visit two and remained stable
through to visit four; see Figure 2F.
Blood pressure
Systolic blood pressure at rest in the supine position was
significantly higher 15.6 (4.3–28.0) mmHg, P = 0.008 for
the insufficient group at visit two after 30 days compared
to the sufficient group. For all other visits, there was no
difference between the groups. After HUT stimulation,
the increase in systolic blood pressure was significantly
higher for the insufficient group at visit two compared to
the sufficient group, with increases of 16.5 (11.1–22.0)
mmHg and 8.1 (2.8–13.4), P = 0.03, respectively.
Table 1. Characteristics of the study participants at baseline by vitamin D group.
Variable Vitamin D sufficient (N = 14) Vitamin D insufficient (N = 13) P-value
Days from screening to entry (Mean  SD) 37.1  26.9 (N = 14) 54.8  27.1 (N = 13) 0.062¹
Age (years) (Mean  SD) 20.5  2.4 (N = 14) 21.7  2.0 (N = 13) 0.13¹
S-25[OH]D (nmol/L) (Mean  SD) 99.9  24.1 (N = 14) 32.0  16.5 (N = 13) 0.0001¹
Weight (kg) (Mean  SD) 70.1  11.1 (N = 14) 78.4  15.4 (N = 13) 0.23¹
Height (m) (Mean  SD) 176  9.7 (N = 14) 174.2  6.0 (N = 13) 0.56¹
Calcium (pmol/L) (Mean  SD) 1.24  0.04 (N = 13) 1.24  0.02 (N = 12) 0.58¹
iPTH (pg/mL) (Median (IQR)) 39 (16-83) (N = 13) 56 (29–130) (N = 12)
Systolic BP (rest)(mmHg) (Mean  SD) 116  11.2 (N = 14) 123  15.2 (N = 13) 0.11¹
Diastolic BP (rest)(mmHg) (Mean  SD) 66.1  6.3 (N = 14) 72.8  12.0 (N = 13) 0.11¹
Heart rate (rest)/bpm (Mean  SD) 56.6  7.2 (N = 14) 67.7  10.1 (N = 13) 0.007¹
Norepinephrine, rest (nmol/L)(Mean  SD) 0.9  0.3 (N = 14) 1.6  0.5 (N = 13) 0.0002¹
Epinephrine, rest (nmol/L)(Mean  SD) 0.1  0.0 (N = 13) 0.1  0.0 (N = 13) 0.66¹
Sex
Women 10 6 0.18²
Men 4 7
Tobacco (last week)
No 13 10 0.24²
Yes 1 3
Alcohol consumption (last week)
No 8 6 0.57²
Yes 6 7
Physical activity (h/week)
0–2 1 8 0.011²
2–7 5 2
7 and above 8 3
¹Based on Mann–Whitney test.
²Based on Chi-square test.
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Diastolic blood pressure at rest in the supine position
was significantly higher [11.5 (3.2–19.7) mmHg,
P = 0.007] at visit two in the insufficient group compared
to the sufficient group, whereas the difference was
insignificant for all other visits. HUT stimulation at visit
two resulted in a diastolic blood pressure in the insuffi-
cient group of 99.8 (91.7–107.9) mmHg and 75.5 (67.6–

































































































P < 0.0001 P = 0.01 P = 0.002
P = 0.003 P = 0.9 P = 0.6 P = 0.6
P = 0.2 P = 0.008 P = 0.005 P = 0.055
P < 0.0001
P = 0.001 P = 0.2 P = 0.9 P = 0.7
P = 0.002 P = 0.1 P = 0.4
P = 0.08 P = 0.03 P = 0.04
Figure 2. (A) 25-hydroxyvitamin D for groups; (B) plasma norepinephrine (NorEp) at rest; (C) Head up tilt test (HUT) increase in NorEp when
raised from supine(rest) to standing (tiltup); (D) HUT ratio for NorEp at tiltup over rest; (E) HUT heart rate (HR) in beats per minute at tilt up; (F)
HUT increase in HR from rest to tiltup - Effect of intervention is calculated as the response values subtracted from the values from the first visit,
for each subject.
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(12.9–35.7) mmHg, P < 0.0001. At the first, third and
fourth visits, the HUT induced an increase in diastolic
blood pressure that was insignificant.
Discussion
The study show an association between S-25[OH]D and
the sympathetic response to HUT stimulation for several
parameters, mainly interpreted to be caused by the vita-
min D + calcium supplementation affecting the SNS by
increasing the NorEp release to the circulation. This giv-
ing rise to a higher response of the heart rate in the vita-
min D insufficient group compared with the sufficient
group. The outcome is not adjusted for daily physical
activity as it was insignificant.
Even after half a year of vitamin-D supplementation,
the insufficient group did not reach the level of circulat-
ing vitamin-D as in the control group. The daily supple-
mentation of 30 microg vitamin-D is the normal
recommended for adults in Denmark during wintertime
and we did not intend to add more than normal accepted
doses to normal youngsters. Given a higher dose of vita-
min-D might have increase the level in the insufficient
group, but other factors might influence the individual0s
level, that is, genetic dispositions.
NorEp was strongly associated with S-25[OH]D at rest;
similar results have been reported in diet studies of rats
(Baksi and Hughes 1984). The effect of a vitamin D3-
depleted diet on NorEp at rest is reversible in rats (Brion
et al. 1978a). The effects of increasing S-25[OH]D by
vitamin D + calcium supplementation on NorEp in rats
and humans at rest are in line. Modulation of the NorEp
response to HUT stimulation during reversal of vitamin
D insufficiency has, to the best of our knowledge, not
been reported before.
Modulation of the heart rate response to HUT stimula-
tion through increase in S-25[OH]D by vitamin D + cal-
cium supplementation has, to our knowledge, not been
reported in humans. Furthermore, it is of interest that
our study was conducted in normal young adults. In rats,
a vitamin D3-depleted diet leads to decreased atrial con-
tractility and vasomotor response when stimulated with
NorEp (Baksi and Hughes 1986; De Novellis et al. 1994);
this advocates for an effect of vitamin D depletion on car-
diovascular tissue. We did not stimulate with NorEp but
with HUT, which leads to increased serum NorEp, and
our modulation of the heart rate response could result in
both an effect on NorEp release and an effect on cardio-
vascular tissue caused by the increase in S-25[OH]D as a
result of vitamin D supplementation + calcium. We had
no intention to be able to distinguish between central and
peripheral effects on the autonomous nervous system of
vitamin-D supplementation. Most likely, the main effect
is on the central parts of the SNS, but peripheral effect
cannot be excluded for the time being.
Conclusion
This study supports our hypothesis that vitamin D sup-
plementation given to vitamin D insufficient young adult
Table 2. Mean  SD for s-25[OH]D, NorEp, heart rate, systolic and diastolic blood pressure at all four visits.
1. (Baseline) 2. (30 days) 3. (90 days) 4. (180 days)
S-25[OH]D (nmol/L) Suff. 99.9  24.1 97.8  27.6 94.4  33.2 96.1  27.1
Insuff. **32.0  16.5 **54.1  15.0 **63.2  16.6 **64.5  8.6
Norepinephrine (nmol/L), rest Suff. 0.94  0.25 0.79  0.39 0.95  0.32 1.33  0.50
Insuff. **1.61  0.48 **1.31  0.61 1.34  0.61 1.19  0.37
Norepinephrine delta (nmol/L), rest to tilt up Suff. 1.14  0.39 0.90  0.38 0.97  0.27 1.02  0.28
Insuff. **0.69  0.41 0.93  0.50 1.09  0.50 0.94  0.30
Heart rate (bpm), rest Suff. 56.6  7.2 56.7  8.0 58.3  12.5 61.2  8.1
Insuff. **67.7  10.1 **68.5  9.9 **68.8  15.2 65.7  11.8
Heart rate delta (mmHg), rest to tilt up Suff. 19.3  12.3 20.3  11.0 17.9  10.0 17.9  12.0
Insuff. 14.8  10.7 24.2  11.4 23.8  14.2 25.7  11.7
Systolic BP (mmHg), rest Suff. 116  11.2 114  11.8 109  11.5 114  6.7
Insuff. 123  15.2 **130  16.1 120  22.0 122  11.8
Systolic BP delta (mmHg), rest to tilt up Suff. 11.7  8.0 7.8  14.3 11.3  9.6 12.0  5.6
Insuff. 12.4  10.7 *16.6  7.7 9.6  7.4 9.7  8.1
Diastolic BP (mmHg), rest Suff. 66.1  6.3 65.0  9.2 66.6  7.9 66.8  5.3
Insuff. 72.8  12.0 **75.7  12.9 68.8  15.9 71.5  7.7
Diastolic BP delta (mmHg), rest to tilt up Suff. 20.3  9.4 11.1  13.7 14.8  8.4 15.5  7.6
Insuff. 15.8  10.2 **24.6  6.4 17.3  7.5 15.8  7.6
Vitamin D sufficient group (Suff.) Vitamin D insufficient group (Insuff.)
Significant differences between groups are marked with * for (P < 0.05) and ** for (P < 0.01).
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modulate their sympathetic in rest and after HUT stimu-
lation. The mechanism behind the modulation of the
response from the sympathetic nervous system is
unknown, but in line with animal studies. No beneficial
effects of vitamin D supplementation were found in the
vitamin D sufficient group. Future trials of vitamin D3 or
1,25-dihydroxyvitamin D supplementation on the SNS
regulatory mechanisms are needed.
We conclude that supplementation of vitaminD and
calcium in normal youngsters with low S-25[OH]D can
modulate the sympathetic nervous system giving rise to
alterations in blood pressure and heart rate. The observa-
tion might be useful in planning the prevention of cardiac
diseases as the vitamin D level in normal young human
beings has not been taken into consideration. The clear
effect on the autonomous nervous system of vitamin-D
supplementation calls for population studies on the
impact of low or normal circulating levels of vitamin-D
on cardiovascular diseases later in life. On the other hand,
the absence of side effects of vitamin-D supplementation
in general opens for interventional studies, adding vita-
min-D to food in general. This should be in a controlled
environment to be ethical acceptable.
Strength and limitations
One of the strengths of this study is the repeated mea-
surement, as it gives insight to the time perspective in the
modulation of the sympathetic response to vitamin D
supplementation. The investigation of healthy young
adults who are free of diseases and conditions is strength
of the study, as it gives a clearer view of the effects with
no confounders as hypertension or cardiac failure.
We have used tablets with vitamin D3 and calcium
because it is a commonly used form of supplementation.
It is well known that the prohormone 25-hydroxyvitamin
D does not in itself exert physiological effects, as that role
belongs solely to 1,25-dihydroxyvitamin D (1,25[OH]D).
We have not measured 1,25-dihydroxyvitamin D levels,
which is a weakness of the study, as 1,25-dihydroxyvita-
min D has been shown to affect contractility by increasing
sensitivity to NorEp of cardiovascular tissues (Bukoski
et al. 1993) and to affect cardiac output in both dogs and
humans (Jahn et al. 1991; Jespersen et al. 1998). Measure-
ment of 1,25-[OH]D might have given better insight into
the physiology behind the effects of vitamin D3 supple-
mentation. Measurement on 1,25[OH]D in serum might
not reflect the intracellular concentration of 1,25[OH]D
as some tissues possess the ability to synthesize 1,25[OH]
D itself (Zehnder et al. 2001). Since 25[OH]D circulates
bound to vitamin D-binding protein, another solution
could be to estimate free 25[OH]D and bound fraction.
The free unbound 25[OH]D could depict the available sub-
strate to a higher degree, than serum 25[OH]D as we have
measured which is composed of both free and bound forms
of 25[OH]D (Jones 2008). Secondly it is a weakness that
the supplementation included both vitamin D3 and cal-
cium. It cannot be excluded that calcium could play a role
in regulation of serum NorEp, but our results does not jus-
tify such a role for calcium, as calcium was indifferent at
baseline visit, but norepinephrine level was not.
The mechanisms behind the effect of vitamin D3 sup-
plementation on NorEp at rest were beyond the scope of
this experiment. Such mechanisms in humans might pos-
sibly involve the activity of phenylethanol-N-methyltrans-
ferase and affect the intra-adrenal storage of NorEp, as a
vitamin D-depleted diet can lead to this condition in rats,
and the condition is reversible with supplementation
(Brion et al. 1978a,b).
To hopefully curb the seasonal variation in S-25[OH]D
expected to affect our measurements, we used a group
with a stable concentration of S-25[OH]D to act as a
control group. A better way of reducing bias might have
been a four arm study with the vitamin D insufficient
and sufficient groups subdivided into two groups each,
where subjects would be randomized to either treatment
or placebo. In such a four-arm study, the concentration
of S-25[OH]D in the placebo groups would fluctuate sea-
sonally, and such a setup should cover a whole season of
12 months. Alternatively a two arm study with start at
summer at zenith for S-25[OH]D and follow-up 30, 90,
and 180 days, would ensure that S-25[OH]D would be
different in the two groups, as the placebo group would
follow the trajectory of the seasonal variation.
These results could give insight into some of the patho-
physiological effects of vitamin D insufficiency and dis-
eases where NorEp levels are affected and treatment of
vitamin D insufficiency is beneficial. However, heart fail-
ure is known for the association between NorEp and
mortality (Cohn et al. 1984), and the beneficial effect of
vitamin D supplementation(Dalbeni et al. 2014) could be
related to the effect of vitamin D supplementation on
NorEp. Our results might have limitations if transposed
to populations with disease. The modulator effect on the
sympathetic nervous system of vitamin D supplementa-
tion could be too small to have an impact or the patho-
physiology behind the disease blocks the pathway, which
is affected by the supplementation.
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